Clorox (NYSE:CLX) Raised to "Hold" at TD Cowen

Clorox (NYSE:CLX - Get Free Report) was upgraded by equities researchers at TD Cowen from a "sell" rating to a "hold" rating in a report released on Wednesday, MarketBeat.com reports. The brokerage currently has a $170.00 target price on the stock, up from their previous target price of $155.00. TD Cowen's target price suggests a potential upside of 4.49% from the company's current price.

CLX has been the subject of several other reports. Barclays boosted their price objective on Clorox from $137.00 to $139.00 and gave the company an "underweight" rating in a research report on Friday, November 1st. DA Davidson raised their price objective on shares of Clorox from $153.00 to $171.00 and gave the stock a "neutral" rating in a report on Monday. JPMorgan Chase & Co. upped their target price on shares of Clorox from $148.00 to $174.00 and gave the stock a "neutral" rating in a research note on Friday, October 11th. BNP Paribas raised Clorox to a "strong sell" rating in a research note on Friday, September 6th. Finally, Citigroup increased their price objective on Clorox from $165.00 to $170.00 and gave the stock a "neutral" rating in a report on Friday, September 6th. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Clorox currently has a consensus rating of "Hold" and a consensus price target of $155.00.

Clorox Trading Up 0.2 %

Shares of NYSE:CLX traded up $0.28 during trading on Wednesday, hitting $162.70. 1,731,057 shares of the company's stock were exchanged, compared to its average volume of 1,245,675. The firm has a 50-day moving average price of $161.89 and a two-hundred day moving average price of $146.58. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08. The firm has a market cap of $20.14 billion, a P/E ratio of 56.69, a PEG ratio of 3.11 and a beta of 0.41. Clorox has a 1-year low of $127.60 and a 1-year high of $169.09.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.36 by $0.50. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The firm had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the firm earned $0.49 earnings per share. The business's quarterly revenue was up 27.0% on a year-over-year basis. Equities analysts predict that Clorox will post 6.81 earnings per share for the current year.

Insider Buying and Selling at Clorox

In other news, EVP Angela C. Hilt sold 1,733 shares of the business's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $165.52, for a total value of $286,846.16. Following the sale, the executive vice president now owns 13,471 shares of the company's stock, valued at $2,229,719.92. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.57% of the company's stock.

Institutional Investors Weigh In On Clorox

Large investors have recently added to or reduced their stakes in the company. Innealta Capital LLC purchased a new stake in Clorox during the 2nd quarter valued at $30,000. Trifecta Capital Advisors LLC increased its position in Clorox by 139.8% during the 2nd quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company's stock valued at $30,000 after buying an additional 130 shares in the last quarter. First Foundation Advisors bought a new stake in Clorox during the 1st quarter valued at about $31,000. Family Firm Inc. purchased a new position in Clorox in the 2nd quarter worth approximately $31,000. Finally, Quarry LP boosted its position in shares of Clorox by 99.1% during the second quarter. Quarry LP now owns 229 shares of the company's stock valued at $31,000 after buying an additional 114 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.